People · Operator
Named in public records as an officer, director or promoter · active 2009–2011 · Other Health Care, Medical Devices
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pontchartrain Lithotripsy, LLC | — | Other Health Care | Pre-Seed | $1.9M | $6.3M | 2010 |
| Osage ArkMo Surgical Services LLC | — | Medical Devices | Pre-Seed | $819K | $8.6M | 2011 |
| Alapaha Florida Surgical Services, LLC | — | Medical Devices | Pre-Seed | $641K | $4.7M | 2011 |
| Bay State Surgical Services, LLC | — | Medical Devices | Pre-Seed | $602K | $10.9M | 2009 |
| Hudson Lithotripsy Llc | — | Other Health Care | Pre-Seed | $500K | $395K | — |
| LA Surgical Services, LLC | — | Other Health Care | Pre-Seed | $500K | $783K | — |
| Ashland Surgical Services, LLC | — | Other Health Care | Pre-Seed | $437K | $421K | — |
| North West Maryland Urological Services, LLC | — | Other Health Care | Pre-Seed | $300K | $470K | — |
| Patuxent Surgical Services, LLC | — | Other Health Care | Pre-Seed | $300K | $470K | — |
| Stonebusters Surgical Services, LLC | — | Other Health Care | Pre-Seed | $264K | $414K | — |
| Western Kansas Surgical Services, Llc | — | Other Health Care | Pre-Seed | $225K | $353K | — |
| Bakersfield Lithotripsy, LLC | — | Other Health Care | Pre-Seed | $135K | $212K | — |
| Seattle Lithotripsy, LLC | — | Other Health Care | Pre-Seed | $108K | $170K | — |
Jeffrey Gerwin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Gerwin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Christopher Gleason | 13 | 35 |
| Matthew Gleason | 13 | 34 |
| Todd Pierce | 6 | 22 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.